Citigroup Reinstates Buy on Ligand Pharmaceuticals, Announces $387 Price Target
Ligand Pharmaceuticals Inc LGND
$287.54
▼ -2.95%
($-8.75)
⬇️ Below Yest. Low
📅 Earnings This Week
Open
$294.84
Prev Close
$296.29
Day Range
$286.22 – $301.93
52W Range
$129.55 – $326.63
Market Cap
$5.76B
P/E (TTM)
38.04
Beta
1.17
EPS (TTM)
$7.42
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1992-11-18 |
| Shares Out. | 20,040,000 |
| Website | ligand.com/ ↗ |
| Phone | 13026365401 |
| Employees | 47 |
| Revenue | $51.7M |
| Gross Profit | $40.4M |
| Net Income | -$13.3M |
| Free Cash Flow | $123.0M |
| Total Assets | $1.53B |
| Total Liabilities | $534.8M |
| Equity | $997.3M |
About Ligand Pharmaceuticals Inc
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Ligand Pharmaceuticals Inc is a publicly traded company under the ticker symbol LGND on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-07-01)